Breast cancer treatment: Drug Kisqali approval expanded for ... - NBC News
WEB3 days ago · The drug was found to reduce the risk of a patient's breast cancer coming back by 25%. The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to ...
New study finds triple-negative breast cancer tumors with an …
WEBApr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Pembrolizumab Boosts OS for Triple-Negative Breast Cancer
WEB3 days ago · Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, early-stage triple-negative breast cancer. The findings, derived from the KEYSTONE-522 trial, strongly support using this pembrolizumab regimen as the standard-of-care therapy for this difficult-to ...
Estrogen a more powerful breast cancer culprit than we realized
WEBMay 17, 2023 · Estrogen can directly induce genomic rearrangements that lead to cancer in a subset of breast cancers, according to a new report in Nature. The findings could inform better testing and treatment for this disease.
New study finds triple-negative breast cancer tumors with an …
WEBApr 2, 2024 · New research suggests that people who have early-stage triple-negative breast cancer and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates.
Breast Cancer News - ScienceDaily
WEB5 days ago · Find the latest news and research on breast cancer, including prevention, treatment, diagnosis, and outcomes. Learn about new discoveries, advances, and challenges in the fight against breast...
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · The clinical trial, sponsored by the pharmaceutical companies Daiichi Sankyo and AstraZeneca and led by Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center, involved 557 patients with...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
WEBAug 9, 2022 · A clinical trial shows that adding pembrolizumab to chemotherapy improves survival for patients with advanced triple-negative breast cancer and high PD-L1 levels. The FDA has approved this combination for both advanced and early-stage disease, but more research is needed for other patients.
3D mammography better at detecting early-stage cancer with ... - ABC News
WEB3 days ago · The study, which analyzed more than 272,000 breast cancer screenings over 13 years, showed that 3D mammography, known as digital breast tomosynthesis, or DBT, identified breast cancer at higher ...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery …
WEB5 days ago · About triple-negative breast cancer (TNBC) Triple-negative breast cancer is the most aggressive type of breast cancer, which has the highest risk of recurrence within the first five years after diagnosis and is associated with worse outcomes compared to other forms of breast cancer. Approximately 10-15% of patients with breast cancer are ...
- Some results have been removed
Skip to content